$BMRN BIOMARIN PHARMACEUTICAL INC Insider Trading Week 11/2019
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in BIOMARIN PHARMACEUTICAL INC in week 11/2019.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 1,000 | 14,390 | 37,000 | |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 1,000 | 14,390 | 336,338 | 335.3 K to 336.3 K (+0.30 %) |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 93.92 | 7,907 | 742,625 | 78,562 | 86.5 K to 78.6 K (-9.14 %) |
| Mar 21 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 93.07 | 3,728 | 346,965 | 59,248 | 63 K to 59.2 K (-5.92 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 9,370 | 0 | 64,681 | 55.3 K to 64.7 K (+16.94 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 94.53 | 7,227 | 683,168 | 55,311 | 62.5 K to 55.3 K (-11.56 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 94.53 | 9,650 | 912,215 | 9,650 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 5,780 | 0 | 17,028 | 11.2 K to 17 K (+51.39 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 94.53 | 1,149 | 108,615 | 11,248 | 12.4 K to 11.2 K (-9.27 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 94.53 | 32,160 | 3,040,085 | 32,160 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Sell | S | 94.09 | 9,597 | 902,982 | 136,304 | 145.9 K to 136.3 K (-6.58 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 12,840 | 0 | 145,901 | 133.1 K to 145.9 K (+9.65 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 94.53 | 9,443 | 892,647 | 133,061 | 142.5 K to 133.1 K (-6.63 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 9,370 | 0 | 86,469 | 77.1 K to 86.5 K (+12.15 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 94.53 | 6,648 | 628,435 | 77,099 | 83.7 K to 77.1 K (-7.94 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 14.39 | 4,000 | 57,560 | 38,000 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 94.53 | 87,080 | 8,231,672 | 87,080 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 94.40 | 4,000 | 377,600 | 335,338 | 339.3 K to 335.3 K (-1.18 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 14.39 | 4,000 | 57,560 | 339,338 | 335.3 K to 339.3 K (+1.19 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 34,780 | 0 | 335,338 | 300.6 K to 335.3 K (+11.57 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 94.53 | 28,143 | 2,660,358 | 300,558 | 328.7 K to 300.6 K (-8.56 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Option Exercise | A | 94.53 | 24,120 | 2,280,064 | 24,120 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 9,630 | 0 | 96,759 | 87.1 K to 96.8 K (+11.05 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 94.53 | 7,083 | 669,556 | 87,129 | 94.2 K to 87.1 K (-7.52 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 94.53 | 23,450 | 2,216,729 | 23,450 | |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 9,370 | 0 | 62,976 | 53.6 K to 63 K (+17.48 %) |
| Mar 19 2019 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 94.53 | 7,169 | 677,686 | 53,606 | 60.8 K to 53.6 K (-11.80 %) |